Intellectual property group IPH has revealed that a limited set of data originating from Spruson & Ferguson’s systems, including client information, was downloaded by an unauthorised third party in last month’s cyber attack.
Coffee brand Vittoria can’t transfer a case over the trade mark for rival Moccona’s instant coffee jar from one Federal Court registry to another, with a judge reminding the company that the court was “well into the 21st century” and could livestream hearings without the need for interstate travel.
Car electronics company Directed Electronics has challenged a ruling that partially dismissed its case over the alleged misappropriation of trade secrets by a former manager, who was found to have pocketed $3.6 million in commissions through a secret agreement with rival Hanhwa.
Monster Energy has been sued by an inventor who claims that the beverage giant infringed his patent for laser etched pull tabs like those used to package its energy drinks.
TCT Group has won orders revoking two patents for hinges held by Polaris IP as well as indemnity costs, with a judge finding the patentee made “unjustifiable” threats of infringement against TCT over its own brand of soft-close glass hinges.
Crown Melbourne has dropped its appeal of a decision by IP Australia that rejected the casino’s application for a patent covering a modified roulette game.
Moccona’s instant coffee jar shape trade mark should be cancelled because the mark is functional and can’t distinguish the company’s goods, the owner of coffee brand Vittoria argues in a trade mark infringement cross-claim.
Sydney law firm Baybridge Lawyers has lost a bid to block a rival firm that’s located in the same office building from registering its ‘LawBridge’ trade mark.
A unit of Purdue Pharma has fired off a cross-claim in Australian drug maker AUPharma’s lawsuit alleging the US drug giant was wrongly granted patent extensions for oxycodone products marketed as Targin.
German pharmaceutical giant Bayer has slammed generic drug make Sandoz’s late bid for documents, which it called an attempt to “divert and distract” Bayer on the eve of a three-week trial over the patents for its top-selling blood clot drug Xarelto.